![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, September 15, 2023 10:17:42 AM
2023-09-14 10:44 ET - News Release
BOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 5,882,036 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $0.43 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.0 million, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.
Recent FWBI News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/24/2024 12:03:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 08:30:18 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 06/17/2024 09:23:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/14/2024 09:15:44 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/11/2024 04:15:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 09:15:42 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/31/2024 09:25:23 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/30/2024 09:32:34 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/30/2024 09:18:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 11:16:09 AM
- First Wave BioPharma Changes Name to Entero Therapeutics • GlobeNewswire Inc. • 05/16/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:26:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 09:26:55 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/13/2024 08:59:07 PM
- First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market • GlobeNewswire Inc. • 05/10/2024 11:55:00 AM
- First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/08/2024 09:16:31 PM
- First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients • GlobeNewswire Inc. • 04/24/2024 11:00:00 AM
- First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference • GlobeNewswire Inc. • 04/15/2024 11:00:00 AM
- First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference • GlobeNewswire Inc. • 03/18/2024 11:00:00 AM
- First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline • GlobeNewswire Inc. • 03/14/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 10:26:27 PM
- First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/05/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/04/2024 10:29:57 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM